HER2/NEU OVEREXPRESSION IN pT1a OR pT1b, N0, M0 BREAST CANCER

被引：0
|
作者：
Petroni, S. [1 ]
Asselti, M. [1 ]
Giotta, F. [2 ]
Quero, C. [1 ]
D'Amico, C. [3 ]
Marzano, A. L. [1 ]
Daprile, R. [1 ]
Salvatore, C. [1 ]
Colucci, G. [2 ]
Simone, G. [1 ]
机构：
[1] NCI Giovanni Paolo II, Anat Pathol Unit, Bari, Italy
[2] NCI Giovanni Paolo II, Med & Expt Oncol Dept, Bari, Italy
[3] NCI Giovanni Paolo II, Senol Unit, Bari, Italy
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷
关键词：
D O I：
10.1016/S0305-7372(10)70053-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [1] \HER-2/neu Overexpression as Prognostic Factor in Small Size Breast Cancer (pT1, N0, M0)
    Petroni, S.
    Giotta, F.
    Asselti, M.
    Quero, C.
    Marzano, A. L.
    Giannone, G.
    Rubini, V.
    Simone, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S134 - S134
  • [2] PT1-T2 N0 M0 BREAST CANCER WITH EARLY RECCURENCE
    Zemni, I.
    Haddad, S.
    Adouni, O.
    Saadallah, F.
    Ben Hassouna, J.
    Hechiche, M.
    Chargui, R.
    Rahal, K.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A62 - A63
  • [3] Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.
    Musolino, Antonino
    Michiara, Maria
    Boggiani, Daniela
    Sikokis, Angelica
    Rimanti, Anita
    Pellegrino, Benedetta
    Martella, Eugenia
    Bozzani, Francesco
    Sgargi, Paolo
    Panebianco, Michele
    Bisagni, Giancarlo
    Falcini, Fabio
    Pinto, Carmine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Clinicopathological Characterization of pT1a,b pN0 M0 Breast Cancer - Impact on Treatment Decision in the ODISSEE Cohort
    Lacroix-Triki, M.
    Radosevic-Robin, N.
    Louis, B.
    Roche-Comet, I.
    Soubeyrand, M-S
    Mely, E.
    Dalenc, F.
    Belkacemi, Y.
    Penault-Llorca, F.
    [J]. MODERN PATHOLOGY, 2014, 27 : 62A - 62A
  • [5] Clinicopathological Characterization of pT1a,b pN0 M0 Breast Cancer - Impact on Treatment Decision in the ODISSEE Cohort
    Lacroix-Triki, M.
    Radosevic-Robin, N.
    Louis, B.
    Roche-Comet, I.
    Soubeyrand, M-S
    Mery, E.
    Dalenc, F.
    Belkacemi, Y.
    Penault-Llorca, F.
    [J]. LABORATORY INVESTIGATION, 2014, 94 : 62A - 62A
  • [6] Bladder cancer pT1G3 N0 M0 - Results of early cystectomy
    Bader, P.
    Spahn, M.
    Woehr, M.
    Frohneberg, D.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 174 - 174
  • [7] Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers
    Musolino, Antonino
    Boggiani, Daniela
    Sikokis, Angelica
    Rimanti, Anita
    Pellegrino, Benedetta
    Vattiato, Rosa
    Sgargi, Paolo
    Falcini, Fabio
    Caminiti, Caterina
    Michiara, Maria
    Leonardi, Francesco
    [J]. CANCER TREATMENT REVIEWS, 2016, 43 : 1 - 7
  • [8] Bladder cancer PT1 G3 N0 M0 - Results of early cystectomy
    Bader, P
    Spalm, M
    Huber, RD
    Echtle, DR
    Frohneberg, DH
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 77 - 77
  • [9] BLADDER CANCER PT1 G3 N0 M0: RESULTS OF EARLY CYSTECTOMY
    Kamecki, K.
    Siekiera, S.
    Krasnicki, K.
    Mikolajczak, W.
    Petrus, A.
    Wronczewski, A.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 323 - 323
  • [10] Breast cancers T1a,b N0 M0 (RPC 2013)
    Lacroix-Triki, M.
    Jacot, W.
    Belkacemi, Y.
    Dalenc, F.
    Cottu, P.
    Rodrigues, M.
    Coeffic, D.
    [J]. ONCOLOGIE, 2013, 15 (12) : 637 - 672
12345